- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | ADALTA LIMITED: Letter to Shareholders, Notice of AGM & Proxy Form | - | ASX | ||
| Di | ADALTA LIMITED: Change of AGM Date | 1 | ASX | ||
| 25.10. | ADALTA LIMITED: Quarterly Appendix 4C and Activities Report | 2 | ASX | ||
| 18.10. | ADALTA LIMITED: RDTI receipt, Advanced Overseas Finding | - | ASX | ||
| 04.10. | ADALTA LIMITED: EW-001 JDC milestone approvals | 2 | ASX | ||
| 01.10. | ADALTA LIMITED: China Representative Office opens | 1 | ASX | ||
| 30.09. | ADALTA LIMITED: Date of AGM & Closing Date for Director Nominations | - | ASX | ||
| ADALTA Aktie jetzt für 0€ handeln | |||||
| 23.09. | ADALTA LIMITED: US FDA grants EW-001 pre-IND meeting | - | ASX | ||
| 18.09. | AdAlta Validates Commercial Viability of IRO Manufacturing Strategy with Oribiotech Deal | 1 | smallcaps.com.au | ||
| 18.09. | Daily Special: Abacus Group, Neu Horizon Uranium, Finbar Group, AdAlta, Sultan Resources | 2 | Finance News Network | ||
| 18.09. | AdAlta Partner Secures Landmark US$120 Million Deal, Validating Manufacturing Automation Strategy | 1 | Finance News Network | ||
| 18.09. | AdAlta (ASX:1AD): A US$120m Deal Just Validated Its Manufacturing Strategy | - | Stocks Down Under | ||
| 18.09. | ADALTA LIMITED: Oribiotech deal validates AdAlta manufacturing strategy | - | ASX | ||
| 15.09. | ADALTA LIMITED: CAR-TCR Summit poster | 2 | ASX | ||
| 10.09. | ADALTA LIMITED: Bilingual BIOSeedin Investor Presentation | - | ASX | ||
| 02.09. | AdAlta Partner to Provide Adapted CAR-T Mesothelioma Therapy in China under Special Access Scheme | 1 | smallcaps.com.au | ||
| 02.09. | ADALTA LIMITED: BZDS1901 special access scheme launch in China | 1 | ASX | ||
| 21.08. | ADALTA LIMITED: Appendix 4G and Corporate Governance Statement | - | ASX | ||
| 21.08. | ADALTA LIMITED: Annual Report to shareholders | - | ASX | ||
| 21.08. | ADALTA LIMITED: Preliminary Final Report | - | ASX |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,090 | +0,09 % | Qiagen zieht an, Siemens Energy schmiert ab: DAX-Ausblick | Der DAX ist in der vergangenen Woche wieder deutlich zurückgefallen. Unter dem Strich büßte das größte deutsche Börsenbarometer 440 Punkte ein und schloss -1,72% tiefer mit 25.181 Punkten. Die höchsten... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,020 | 0,00 % | Stifel bekräftigt Kaufempfehlung für Cogent Biosciences nach ESMO-Daten | ||
| ENLIVEN THERAPEUTICS | 44,250 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year | Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness
Enliven continues preparation for late-stage... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 18,155 | -0,14 % | Mineralys Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 126,72 | +0,07 % | Oppenheimer raises Kymera Therapeutics price target on drug data | ||
| TANGO THERAPEUTICS | 22,710 | 0,00 % | Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside? | ||
| BAMBUSA THERAPEUTICS | 14,900 | -0,60 % | Bambusa Therapeutics, Inc.: Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering | BOSTON, Oct. 29, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Nasdaq: BBTX) ("Bambusa Therapeutics" or " Bambusa"), a clinical-stage biopharmaceutical company developing next-generation, long-acting... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,025 | -0,12 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| SUMMIT THERAPEUTICS | 16,030 | 0,00 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| VOR BIOPHARMA | 19,680 | 0,00 % | Vor Bio Down on Q3 Results | ||
| KINIKSA PHARMACEUTICALS | 92,10 | -0,15 % | Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales | ||
| PRIME MEDICINE | 4,720 | 0,00 % | Prime Medicine, Inc.: Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease | -- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation... ► Artikel lesen | |
| ERASCA | 14,330 | -0,14 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| ABSCI | 11,125 | -0,04 % | Jefferies nimmt Absci mit "Buy" auf - Potenzial bei Wirkstoff gegen Haarausfall im Fokus | ||
| NURIX THERAPEUTICS | 26,780 | -0,07 % | Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue | SOUTH SAN FRANCISCO (dpa-AFX) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period... ► Artikel lesen |
ADALTA LIMITED gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,001 (-50,00 %) liegt der Kurs bei 0,001 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADALTA LIMITED finden Sie auf Wallstreet Online.